Table 3.
Project A2: Subjects’ characteristics (sex, age)
| BE | BO | DR | GÖ | HA | MA | TÜ | Total | Sex (male/female) | Mean age (± SD) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, T1 | 22 | 2 | 9 | 6 | 12 | 5 | 9 | 65 |
36/29 (55.4% / 44.6%) |
32.7 (± 9.3) |
| Patients, T2 | 15 | 0 | 7 | 2 | 5 | 3 | 6 | 38 |
21/17 (55.3% / 44.7%) |
32.9 (± 8.8) |
| Controls, T1 | 21 | 0 | 0 | 0 | 2 | 2 | 10 | 35 |
15/20 (42.9% / 57.1%) |
30.2 (± 8.6) |
| Controls, T2t | 19 | 0 | 0 | 0 | 0 | 2 | 3 | 25 |
14/11 (56.0% / 44.0%) |
32.0 (± 9.3) |
65 patients were assessed with MRI in project A2 before therapy (T1), 38 were assessed a second time after therapy (T2). They were randomly assigned to one of two treatment groups (i.e., either SEKT or FEST). The present table shows how many subjects were measured in each center (BE Berlin, BO Bochum, DR Dresden, GÖ Göttingen, HA Hamburg, MA Marburg, TÜ Tübingen). Additionally, a group of healthy control subjects was measured